Glythera United Kingdom

Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:

- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)

PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems  

- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars   

PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept 

Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners  to progress applications of PermaLink™ and PermaCarb™ technologies. 

We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™ 

Organisation type
Membership affiliation
Dr Ian Evetts
Dr Ian Evetts
LinkedIn logo Commercial Director 
Dr Dave Simpson
Dr Dave Simpson
LinkedIn logo CEO